Related Videos
Video
Matthew Davids, MD, MMSc discusses time-limited AVO triplet therapy
In a new study published in the Journal of Clinical Oncology and presented at #ASH24, Matthew Davids, MD, MMSC, of Dana-Farber Cancer Institute, shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk CLL patients.
Video
Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research ...
Video
Blood Cancer Research: Clinical trial helps younger patient
Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.